A CAR-T biotech’s dramatic turnaround, and drugmakers’ tactics to drive more scripts
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Kelonia Therapeutics survived three near‑bankruptcy crises before being bought for $3.25 billion by Eli Lilly.
- Eli Lilly announced a $3.25 billion acquisition of Kelonia Therapeutics, securing a CAR‑T platform.
- Bryan Roberts backed Kelonia through his VC firm, helping finance its turnaround and eventual sale.
- Prescribery is being tapped by drugmakers as a low‑cost telehealth partner to generate additional prescriptions.
- Katie Palmer highlighted pharma’s strategy of using bargain‑basement telehealth providers to push more scripts.
- Medicare delayed its obesity‑drug coverage pilot, slowing patient access to new treatments.
Why it matters: Eli Lilly secures a $3.25 billion CAR‑T platform, expanding its oncology pipeline, while investors like Bryan Roberts reap massive returns; pharma’s Prescribery deals boost prescription volume, but Medicare’s delayed obesity‑drug coverage stalls patient access.
